Executive
Board

130th Meeting Executive Board
Taipei (Taiwan), November 24th-25th, 2016

Summary Minutes
Participants:
EB Members
Maurizio Ferrari(MF)
Graham Beastall(GB)
Sergio Bernardini(SB)
Tomris Ozben(TO)
Rosa Sierra-Amor(RSA)
Vanessa Steenkamp (VS)
Rolf Hinzmann(RH)

President
Past President
Secretary
Treasurer
MemberMemberCorporate Representative (Roche)

Invited guest:
David Kinniburgh

NAFCC President(DK)____________

1

The 130th Meeting of the IFCC Executive Board was held in Taipei (TW), at the “Pacific Business Hotel”, 495,
Guangfu South Road, Xinyi District, Taipei, Taiwan - Meeting room A

1.

Preliminaries

1.0
Welcome and opening remarks from the President: thanks to Prof. Fang for kind hospitality.
MF and all the EB sent congratulations to Howard Morris for his election. He has been invited at the EB but
cannot participate.
1.1.129 Minutes of 129th EB Meeting, Philadelphia (PA, US)EB approved the Full Minutes and the Summary Minutes from the 129th Meeting.
Action List from 129th EB Meeting
Almost all the Actions from the EB in Philadelphia have been done or are well in progress.

Strategic Plan session
EB reviewed the great progress with the Strategic Plan also considering the results from the SWOT analysis.

2.
-

-

Full Member Societies
Russian new Full Member Society creation, 5 Societies merged on the «Federation ofLaboratory Medicine» (FLM) (the actual member Russian Scientifically-Practical Society ofSpecialists in Laboratory Medicine, Russian Scientifically-Practical Society of Specialists inLaboratory Medicine, Russian Association of medical laboratory Diagnostics, National
association of laboratory, Personalized and Translation Medicine, Association of
manufacturer of tools for diagnostics, Association of specialists and organizations“Federation of Laboratory Medicine”).
Merging of Ukrainian Full Member “Ukrainian Society of Clinical Laboratory Diagnostics(USCLD)” with the Affiliate Member “Association of Clinical Chemistry and Laboratory
Medicine of Ukraine (ACCLMU)”. New name: “Association of Clinical Chemistry andLaboratory Medicine of Ukraine (ACCLMU)”.

4.
Affiliate Members
No items
3.
Corporate Members
RH report: almost all the big IVD Companies are implementing the MedTech Europe. In Athens andin Durban it will be applied except for direct sponsorship that will be implemented in 2018.
The TF-POCT satellite symposium at the WorldLab is not lined up with MedTech because is a mix
academic and corporate event; the two parts have to be clearly separated.
The Scientific Program of the Congresses has not to include turist promotion.
8.13. Joint Committee for Traceability in Laboratory Medicine (JCTLM
GB: the JCTLM Executive Board is in discussion with the Board of the International Council forStandardisation in Haematology (ICSH) about ICSH becoming a member of JCTLM – preferably at
Executive Board level. The Chair of the JCTLM Executive Board or 2017/2018 has been confirmed
as Gary Myers. In this capacity GM is a consultant member of IFCC SD.
A new category of ‘JCTLM stakeholder member’ has been created. This will allow IVD companies tojoin JCTLM for the first time .
The Secretariat of JCTLM for 2017/18 has been confirmed as BIPM (specifically Robert Wielgosz
and Stephanie Maniguet). BIPM has held the Secretariat since JCTLM was formed in 2002.
GB will represent the IFCC EB on the JCTLM Executive Board for the two years 2017/18. Led by
IFCC (GB) JCTLM has restructured into two main areas:
1) JCTLM Database which continues to increase the number of reference materials, reference
methods and reference laboratories it lists. Many of the reference materials and methods come2

from IFCC activities. There is a dramatic increase in the number of reference laboratories in
China, which has embraced traceability in a big way.
2) To introduce a new website (www.jctlm.org) to provide educational resources on theimportance of traceability in laboratory medicine. This website has been built by InSoft using
sponsorship obtained by GB. The IFCC Office has kindly agreed to operate and update thewebsite, is presenting symposia and/or posters at all the IFCC congresses in 2017 and at the
AACC meeting. GB is planning a conference for December 2017 at which Sergio Bernardini will
be a speaker.
15.0 Financial Matters15.1 Treasurer’s Report
EB received an update on finances by TO.
Budget 2016 (CHF) actual at September 2016: total income 580.000 (proposal), 876.333 (actual
YTD); total expenses 1.877.341(proposal), 1000.061 (actual YTD); net loss -1.297.341 (proposal),-123.728 (actual YTD).
Proposal 2017: total income 981.259 total expenses 1.692.702 ; net loss -711.000
Received dues 2016 (CHF): Full Members 168.338 (90,2%); Affiliate Members 3575 (74,5%); CMs
290.092 (89,5%).
EB received an update on the investment policy by TO.
The net performance of Investments at LGT Bank in 2015 was a loss of -74.266, in 2014 a gain of+48.627 CHF.
EB agree to move the current portfolio from LGT to Credit Suisse portfolio with 0.20 % investment
fee. At the beginning of January MF, TO and PB will meet in Milan to look at the budget 2016 andthen decide the necessary cuts to the budget of functional Units.
8.0
Scientific Division (SD)EB noted the Minutes of the SD Meeting
SD structure and commitments and Chair position
The Chair of the SD, Ian Young, will end his 2nd term in December 2016. EB agree to nominate
Chair of the SD for the term 2017-2019, Philippe Gillery.
PG presentation of the SD strategic Plan in the next term:
Maintain and amplify the high level of involvement of IFCC-SD in the field of standardization /harmonization: continuation and/or completion of ongoing projects, robust performance
management and adherence to agreed timelines, picking up priority measurands from theharmonization consortium, identification of new areas, in collaboration with key partners (Drugs,
molecular biology, proteomics).
Actual committees: Autoimmune tests should shift from a WG to a Committee, C-NPU (links withother international organizations), C-MD (creation of an IFCC network / identification of new tests),
C-TLM (maintenance of IFCC networks (eg HbA1c), C-RIDL (establishment of reference values
worldwide), C-STFT (important advances in standardization / harmonization and clinical outcomes).
Created committees C-HAT (previous WG-HAT), jointly with EULAR.
Closed committee: C-RSE (transformed in to a WG on pancreatic lipase)
Working groups: performance manage the creation / evolution / productivity / closure of WGs on
specific tasks within agreed timeframes. Near to achievement: WG-CDT, WG-HbA1c (reference
procedures and/or materials). New scientific items: eg WG-PAPPA, WG-CSF, WG apolipoproteins(to be established); collaborative WGs: eg WG HbA2 (ISTH), WG-SAU (NKPED), WG-SIA(ADA/EASD), WG-BMA (IDF); WGs to close and/or transform: WG-HAT to C-HAT; new WGs on
specific
application:
WG-cMSP(generalreflexion
tospecific
applications)(egapolipoproteins/hepcidin).
Maintain and amplify the visibility of IFCC scientific activities inside and outside IFCC
Active participation in all IFCC and regional federation meetings, systematic preparation of a special
issue in the official IFCC journal every 2 to 3 years (last achievement: 2016 in CCA), participation in3

scientific meetings of clinical societies in areas covered by SD (eg endocrinology, immunology,
cardiology), participation and reinforced relations with partners (BIPM, NMIs, WHO), focussing on
specific expertise areas of SD (eg HbA2 for WHO), increased interactions with other IFCC divisions
or task forces for identifying new markers suitable for standardization / harmonization, in
cooperation with corporate members (markers of diabetes (AGEs), markers of neurodegenerative
diseases , markers in genomics).
Prepare the future: focus SD activities on new areas of clinical chemistry and laboratory medicine(eg molecular biology, proteomics), select and involve new members in SD Cs and WGs (key actors
getting older or retiring, new skills required in new areas of interest). Involvement of young scientists
with EB support, ensure the maintenance of IFCC networks (cf C-TLM), close co-operation withother IFCC divisions, including any new focus on innovation.
RH suggest two relevant issues regarding standardization and traceability: HbA1C, glucose andcontinuous glucose subcutaneous monitoring.
MF suggested the implementation of a new IFCC Division because many new issues should bemanaged in the next future by IFCC: Predictive Medicine and Genomics, LC/MS, GC/MS andClinical Laboratory, Metabolomics and Clinical laboratory, Management of “Big Data” Health andInformation Technology, Nanotechnologies, microfluidics and POCT development, Theranostics,
Laboratory Economy, Health Technology Assessment and Lab. Management, Eco-sustainability.
The new Division should include SD and EMD in the discussion of these issues and has to becoordinated with them.
EB agree to give to SB the task of making an Action Plan about the new Division. The Action Plan
will be submitted at the next EB (Milano, February 2017).
GB: The new Division Executive Committee should be nominated at the Q4 2017. The TFs
reorganization should provide some finance to the new Division.
9.0
Education and Management Division (EMD)
EMD Membership update suggested by LL:
EMD-C: E. Frank (Vice Chair), P. Fortina (Secretary), AL Maselli (Member 2nd term);
C-CMBC: E. Lianidou (Chair 2nd term, V. Haselmann member 2nd term), A Watanabe (member 2nd
term)
C-AQ: A. Thomas (Chair 1st term), A. Haliassos (2nd Term), L. Khoroskaya (member 1st term)
C-EBLM: K. Rodriguez-Capote (member 2nd term)
C-CLM: S Yenice (Chair 2nd term), M Kuti (member 2nd term)
WG-LEPS: L. Sciacovelli (Chair 2nd term)
WG-FC: U. Sack (extra term of two years)
DQCML: E. Amann (Chair 1st term)
EB approved.
VLP update
Approved applications for 2016: Manuel Morejón (Sociedad Cubana de Patología Clínica), Jousif
Bilto (Jordan Society for Medical Laboratory Sciences), Karel Tomberg (Estonian Society forLaboratory Medicine), Ioana Brudasca (Romanian Association of Laboratory Medicine), Hilda
Matarira (Association of Clinical Biochemists in Zimbabwe), Osama Najar (Palestinian Medical
Association), Sun Fei (Chinese Society of Laboratory Medicine), Elizabeth Arcellana Nuqui(Philippine Council for Quality Assurance in Clinical Laboratories), Mabel Charles Davies(Association of Clinical Chemists of Nigeria), Gye-Cheol Kwon (Korean Society of Clinical
Chemistry, Mohamed Shaarawy (Egyptian Society of Clinical Chemistry), Maria Alejandra Arias(Confederación Unificada Bioquímica de la República Argentina), MVR Reddy (Association ofClinical Biochemists of India).
MF will contact Abbott to ask for 2017 funding.

410.
Communications and Publications Division (CPD)
CPD membership: P. Veervart and B. Jordan ended their 2nd term. The CPD EC suggested two
nomination: Eduardo Freggiaro (secretary) and Peter Bialk (member). EB approved.
EB received an update by KA.
The IFCC Website continues to be a major communication tool, the repository of resources and awindow for IFCC members and functional units, the hosting platform for IFCC initiatives andprojects. Several major and minor updates have been done in 2016.
The new IFCC app facilities communication of IFCC news and publications and it has been wellreceived by IFCC member societies and scientists. The IFCC e-News have a new logo, Flip & PDF
versions and continues to expand its focus to offer visibility to IFCC members and their activities.
The prototype for version in Spanish has been identified. There is regular contributions from
Divisions and collaboration with LMI, for both English and Spanish editions.
The new IFCC e-News FLASH (from May 2016) provides quick updates on IFCC activities; from2017: 6 issues/year + special issues for breaking news!15.000 professional readers all over theword. The IFCC eJournal has been PUBMED indexed as of 2016. The IFCC Diagnòstico in Vitro
DiV has been re-launched and as PDF and flipping version, 4 issues/year with featuring News andscientific articles + interviews and news from the Ibero-American Countries. It has been promoted
via IFCC channels and via the Web Radio El Microscopio.
RSA:instructions for authors (ideally following eJIFCC guidelines) and editorial membership should
be increased for paper review.
The C-IeL continues to work closely with the C-DL and Insoft in developing electronic/distancelearning materials and access for IFCC members utilising the ‘e-Academy’. Total items publishedbetween June 2015 (launch) and Sept 2016: 46 webinars and 50 external links. Webinars in
preparation include the following topics: immunoassay, uncertainty and traceability,
BNP/NTProBNP, GH/IGF1, the R-A-A system and the first three of a comprehensive set of modules
on serum proteins and immunology. An eAcademy membership database is also being developedwith Insoft. IFCC Publi Reltions tools: the PR brochures 2015-2017 have been completed for for
English, Arabic, Chinese, French, Greek, Italian, Polish, Russian, Spanish, Turkish, Portuguese,
German and Farsi as well as the slide kit on IFCC organization, the slide kit on role of Lab Medicine
and its role in Healthcare Delivery The IFCC CPD annual survey assessed effectiveness of IFCC
communication tools and potential barriers. 61 Societies responded and the number of responses
was 636. Three out of four responders visit the website and 37,3 % were aware of EB activities/TF,
31,7 % of CPD activities, 32,0 % of EMD activities and 35,9% of SD activities.
eAcademy support
EB met the J.F. Pierson-Perry (Siemens representative in SD). JFPP in principle was agree tocontinue support the eAcademy. A detailed proposal for 2017 will be send by CPD to JFPP as soon
as possible.
7 Committee on Congresses and Conferences (C-CC)
EB discussed and approved the revision of WorldLab Guidelines.
EB discussed and approved the EuroMedLab Guidelines EFLM amendments.
RH suggest to promote as much as possible the MedTech Etical Code Guidelines to NSs. EB
agree.
7.2
IFCC WorldLab Congresses
7.2.23 IFCC WorldLab 2017, Durban (ZA)
Durban, October 22nd-25th, 2015
EB received an update by VS. Two satellite meetings have been approved: POCT and Biomarkers
for Diabetes. Two other satellite meetings have been proposed: laboratory Quality management andPersonalized and Predictive Medicine. The Organizing Committee would like to support 150
delegates from developing countries to attend. TO will define the expected balance for IFCC, thenEB will establish its own support for scholarships. This has to be done as soon as possible
considering the time needed to obtain VISA for many attendants.

5

The provisional expenses are in the order of 500.000 CHF. There is concern about the lack of anadequate support from international IVD.
ICPLM meeting has not been approved in the present form, and it has been suggested that its
duration be reduced to 1 day and the Congress held in the same area of the WorldLab sharing
some speakers. MF: the minimum number of attendants has to be defined. GB: the ICPLM has to
be closely linked to TF-PLM activities to make sense for IFCC.
7.2.24 IFCC WorldLab 2020, Seoul (KR)
Seoul, May 24th-28th, 2020
EB received an update from MF, the congress planning is ongoing.
EB decided to open the bid for WorldLab 2023
7.3
IFCC Regional Congresses of Clinical Biochemistry and Laboratory Medicine
7.3.1.14 APFCB Taipei, 2016
Taipei, November 26th-29th, 2016
7.3.1.15 APFCB India, 2019
Jaipur – Rajasthan, 17th-20th November 2019
7.3.2.22 EuroMedLab 2017, Athens (GR)Athens, June 11th-17th, 2017
A wide attendance is expected, the Scientific programme in excellent.
7.3.2.24 EuroMedLab 2019, Barcelona (ES)Barcelona, May 19th-23rd, 2019
EB received an update from MF. The COC start work in a very constructive way.
7.3.4.23 COLABIOCLI Uruguay, 2017
Punta del Este, 17th-20th September, 2017
7.3.6.15 AFCB Congress
The Congress 2018 will be held in Palestine
7.3.7.5 AFCC
EB receive an update by VS on future congress place: probably it will be in Durban
7.4
IFCC Specialised Conferences
7.4.1 Roche Bergmeyer Conference will be held in March 2018, Eibsee, Germany. Title:“Coagulation”. IFCC will not longer involved in the organization because of the application of
MedTech Ethical Code.
7.40 Other Business
WASPaLM Congress 2017 in Kyoto: an IFCC session has been organized.
6.0International and Professional Organisations

6.1 World Health Organisation (WHO)See SP comments
6.2
Clinical Laboratory Standards Institute (CLSI)
Larry Kricka will not longer be the liaison with CLSI, EB is looking for an officer able to substitutehim and will contact LL and PG for an advice.
Update of CLSI-IFCC Joint Projects:

6

In revision: “Analysis of Body Fluids in Clinical Chemistry” and “Toxicology and Drug Testing in theClinical Laboratory”, “Collection, Transport, Preparation, and Storage of Specimens for Molecular
Methods”; “Evaluation Methods and Analytical Performance Characteristics of Immunological
Assays for Human IgE Antibodies of Defined Allergen Specificities”;
Published: “Verification of Comparability of Patient Results Within One Healthcare System” , “Serum
Indices in the Clinical Laboratory”, “Mass Spectrometry in the Clinical Laboratory: General Principles
and Guidance”“Evaluation of precision performance of quantitative measurement methods”, “User verification of
precision and trueness”, “User evaluation of between-reagent lot variation”, “Protocols fordetermination of limits of detection and limits of quantitation”, “Defining, establishing, and verifyingreference intervals in the Clinical Laboratory”, “Reporting critical, life-threatening or life-alteringlaboratory results”,“Body fluid analysis for cellular composition”, “Performance of single cell immune
response assays”, “Proficiency testing (External Quality Assessment) for molecular methods”,"Guidelines for comparison of glucose results measured by methodologies which use different
sample types", “Diagnostic Nucleic Acid microarrays”, “Point-of-Care connectivity”;
Reaffirmed: “Application of biochemical markers of bone turnover in the assessment and onitoringof bone diseases”, “measurement of free thyroid hormones”, “Immunoassay interference byendogenous antibodies”, “Use of external RNA controls in gene expression assays”,“Implementation guide of POCT01 for healthcare providers”;
In development: “Assessments laboratory internal audit programs”.
RH: CMs are really interested in the CLSI guidelines that are largely adopted in US and should bealso promoted in Europe.
6.4
International Union of Pure and Applied Chemistry (IUPAC) liaison GB
GB: IFCC and IUPAC continue to collaborate as co-owners of and contributors to the Nomenclature,
Properties and Units (NPU) Steering Committee. GB (EB) and IY (SD) serve on the Steering
Committee for IFCC. The Steering Committee meets mainly by Skype but a face to face meeting
was held in Copenhagen in May 2016. The business of the Steering Committee falls into two areas:
1. Operational and developmental aspects of the NPU database, which is widely used in
Denmark, Sweden and Norway
2. Efforts to persuade the International Health Terminology Standards Development
Organisation (IHTSDO) to map NPU terminology against the SNOMED CT system of healthterminology. Graham Beastall and the IUPAC Treasurer will attend a meeting with IHTSDOin London on 5 December to pursue this aim
Future involvement of IFCC in the project is dependent on SD continuing to support the C-NPU ( alongstanding SD committee). It is also dependent on finding replacements GB and IY on the NPU
Steering Committee. EB will propose to Howard Morris to replace GB.
6.13 World Association of Societies of Pathology and Laboratory Medicine (WASPaLM) –See SP note
6.23 International Standards Organisation (ISO) - liaison GB
Liaison within EB as 2017: RSA
EB noted the documents related to ISO/TC 212/Working Group 2 Meeting
6.50 International Laboratory Accreditation Cooperation (ILAC)
No specific items to discuss
5. Regional Organisations
5.01 Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine
Joint meeting IFCC-APFCB on Monday November 28th 09.00-13.00 followed by lunch at Pacific
Business Hotel – Meeting room A
EB noted the APFCB report
EB reviewed the IFCC-APFCB MoU that is going to be renewed.

7

5.02

COLABIOCLI2019 Congress in Panama

5.04

European Federation of Clinical Chemistry and Laboratory Medicine
No specific comment

5.05

Arab Federation of Clinical Biology
No specific comment

5.06 African Federation of Clinical Chemistry
EB received comments from VS
Radio Africa – El Microscopio
The African Federation of Clinical Chemistry and Laboratory Medicine (AFCC) launched Africa
Radio on 16th June 2016. This was announced by ZACB, AFCC and also on El Microscopio an
IFCC supported internet radio programme. Africa is a vast continent with long distances between
the members to meet physically and frequently. The aims were communicate effectively through theinternet radio to spread and share knowledge, information, data, experiences and skills in all aspectof laboratory medicine practice especially l that which would impact and improve the quality ofclinical laboratory results; to link laboratories in AFCC, IFCC and others eg. diagnostic industry,
ASLM, etc.; to promote consultancy and quality value of laboratory medicine.
AFCC wish to apply for IFCC funding for the internet radio equipment, infrastructure, consumables
and labour to set it up in Harare, Zimbabwe, activities for radio interviews. El Microscopio will
provide consultancy and advisory service if requested. IFCC funding requested: 49.405 USD inthree years(first year 23.000 CHF).
EB decided that IFCC cannot sustain Radio Africa presently and that IFCC cannot support theRadio-Microscopio project in LATAM after the end of 2017.
5.07 North American Federation of Clinical Chemistry and Laboratory Medicine
EB received comments from DK.
16. Organizational Matter
16.1 IFCC Office- During last years IFCC tried to obtain from MZ Congressi more space for the IFCC office. We
have now been offered to move from the 6th to the 7th floor of MZ premises, at an yearly cost of
CHF 20,000 (actual yearly rental cost is CHF 14,250). The new office will be 36 m2, comparedto the actual 18 m2, have space for 4 working stations and a table to have small meetings.
The 7th floor of MZ Congressi will be restructured, offering among other facilities, a more
spacious common meeting room. The actual rental conditions, remain unchanged (warehouse,monthly, common spaces use etc..).
EB agree with new MZ offer. The moving of the office will be done during the end of the year
holidays.
-

At the end of 2016, the bid for the WorldLab Congress to be held in 2023, will be launched.
In early 2017 the contract with PCO MZ Congressi (valid until the end of 2020), has to besigned in order to allow the beginning of activities of the WorldLab organization.
EB agree to extend the already existing contract until the end of 2023.

16.3 IFCC Nominations Committee
Call for nomination for the Treasurer and Secretary (2018-2020) has been distributed, deadline toreceive nominations: December 15th, 2016. To note that the Ballot will take place from April 1st to
30th, 2017.
Election procedure of the Regional Federations’ Representatives at the EB (2018-2020).

8

EB received an update on behalf of GB: EFLM internal decision was that the EB will indicate acandidate inside the EB (probably the President), nevertheless if another candidate will come fromEFLM members, there will be a ballot. In any case, the nomination of the candidate indicated by the
EFLM EB, has always to be presented by his NS. Moreover any single country can submit acandidature and this is in agreement with the IFCC rules.
16.40 Other business
13.0

Task Forces: updates by the EB members liaison with TFs

13.01.01 Task Force on Ethics (TF-E) – liaison MF
EB approved the Chair’s proposal to confirm the 2nd term of T. Higgins and C. Sekadde-Kigondu,
while a call for nominations to substitute E. Arcellana-Nuqui and K. Okhan Akins’ membership, willsoon be issued.
13.01.02 Task Force on Paediatric Laboratory Medicine (TF-PLM) – liaison SB- ICPLM meeting (see 7.1)
- A call for nominations will be issued to substitute M. Geaghan whose 2nd term will finish at the endof 2016.
13.01.03 Task Force on Pharmacogenomics (TF-PG) – liaison MF
the TF has to be rebuilt, all members except M. Linder, are in extra term since two years.
13.01.04 Task Force on Chronic Kidney Disease (TF-CKD) – liaison GB
the TF has to be rebuilt, except the Chair, all members’ 2nd time in office will finish at the end of
2016. New Liaison as of 2017 RSA.
13.01.06 Task Force for Young Scientists (TF-YS) – liaison GB
EB received the report by the Task Force Chair: Pradeep Dabla
Achievements during 2016: update to membership of core group (35 Corresponding Members andgrowing), regular meetings and discussions by social media, ublication of Research Guide in bothtext and webinar (e-Academy) format, TF meeting held during General Conference in Madrid in
March 2016, session on scientific writing in Harare, Zimbabwe in June 2016, session in Lagos,
Nigeria in October 2016, open workshop on the YS workforce planned for Taipei in November 2016,
symposium planned at ACBICON in Mangaluru, India in December, complimentary Educational
Webinar: ISO Accreditation: New Trends and Global Differences – September 2016, project Award
from FEN to establish ‘Lab Surfing’ – see www.lab-surfing.com , regular updates to the TF-YS
pages on the IFCC website
Plans for 2017: TF meeting at EuroMedLab Athens, June 2017, open session at EuroMedLab
Athens, June 2017, symposium at WorldLab Durban, October 2017, Collaboration with WASPaLM
to support YS session at WASPaLM congress in Japan, November 2017, further webinars (TBA),
promotion of ‘Lab Surfing’, Research Guide.
New Liaison as of 2017 VS.
13.01.07 Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) – liaison TO
Jordi Ordoñez-Llanos, MD, PhD is completing his second term at the end of 2016. EB approved
Fred Apple as the new chair of the TF-CB. A call for nominations to appoint four positions ofMembers in the TF- CB was recently circulated to the IFCC member societies (deadline to receive
nominations December 12th, 2016).
Fred Apple proposed the following names for the TF-CM to be approved by the IFCC EB:
Laboratory members: Peter Kavsak PhD, Canada (IFCC Canada), Amy Saenger PhD, USA (IFCC
USA); Emergency Medicine members: Louis Cullen MBBS PhD, Australia – Clinical non IFCC
member, Richard Body MB ChB PhD, England - Clinical non IFCC member; Cardiology Members:
Nicholas Mills MD, Scotland - Clinical non IFCC member, Torbjørn Omland, MD Norway - Clinical9non IFCC member; Consultants: Jordi Ordoñez-Llanos MD PhD, Spain (IFCC Spain), Allan Jaffe
MD, USA (IFCC USA)The call for nomination is open. In any case the members not nominated by IFCC NSs (clinicians)
will be nominated as “invited members”.
13.01.08 Task Force on POCT (TF-POCT) – liaison RSA
no specific items
13.01.11 Task Force on Proficiency Testing (TF-PT) – liaison RSA
no specific items
13.01.13 Task Force for Geriatrics lab. Medicine (TF -GLM) – liaison SB
No activity at all. EB decided to close the TF.
13.02 Professional Exchange Programmes
EB updated the PSEP 2017 (Eyob Abera Mesfin, Ethiopia) and PMEP 2017 (Lara Popoola
Omolara, Nigeria) applications. PSEP 2016 Jorge Marco Díaz-Garzón, Spain; Nguyen Huu Hieu,
Vietnam; Aysegul Hanikoglu, Turkey; Wafa Omer, Pakistan; Raylton Chikwati, Zimbabwe. PMEP
(Ayoub Rezeq, Palestine).
13.03 Roche Travel Scholarships
EB updated on scholarships allocation
EB agree to grant 5 travel scholarships for EuroMedLab – Athens, 2 for COLABIOCLI Congress in
Punta del Este, 10 for WorldLab - Durban.
Additionally, the Jocelyn Hicks – Past President, will support 4 scholarships to be bestowed in
Durban.
8.0
Scientific Division (SD)
Chair’s report to the EB
Membership: EB agree to nominate Vice –Chair Krista Cobbaert
C-HAT: MOU with EULAR, advertise for Chair and Members
WG-SHbA2: proposed Chair Andrea Mosca. Three years to complete.
WG-SCDT: completed and closed at the end of 2016.
WG-HAT, will become C-HAT
WG-cMSP will be closed
New WG proposal: reference methods for pancreatic enzymes (Grote-Koska); WG on
measurements (Grote-Koska) Apolipoproteins by multiplex MS assay (Cobbaert ), WG on GH and
IGF1-1 (Lentjes), WG on fecal immunochemistry methods for hemoglobin (TBC).
Representation at the JCLM WG-2: continue.
EB approved the proposal of SD for 2017.
ICHCLR.
GB: AACC will not continue to lead the ICHCLR project. IFCC is the only organisation that is
capable of providing ongoing leadership of the ICHCLR project. Therefore, there are two options for
IFCC at this stage : 1)closure of the ICHCLR project; 2) Examine the feasibility of IFCC taking aleadership in the operation of ICHCLR. Nevertheless is not possible for IFCC to conclude at thisstage that IFCC should take leadership of the operation of ICHCLR.
GB recommend to establish a short term group to examine the feasibility of IFCC taking aleadership role in the operation of ICHCLR. The group should comprise a member of EB, a memberof SD, Gary Myers and Greg Miller and should be be empowered to consult with the AACC Board of
Directors, current supporters of ICHCLR and the IFCC Office team, the group should report back by
the end of May 2017 to allow for discussion within SD and EB at EuroMedLab Athens in June 2017.
EB agree with the proposal.

1011.1 IFCC Awards
To receive update by MF on WorldLab Durban Awards’ sponsorships:•
IFCC Distinguished Clinical Chemist Award - IFCC
• IFCC Distinguished International Services Award (1981-1987) - IFCC-Henry Wishinsky• Award for Distinguished International Services (since 1990) – SIEMENS• IFCC Award for Distinguished Contributions in Education – ABBOTT MOLECULAR (support
pending “Conference Vetting System” approval)• IFCC-Abbott Award for Significant Contributions in Molecular Diagnostics - ABBOTT(support
pending “Conference Vetting System” approval)• IFCC Distinguished Award for Laboratory Medicine and Patient Care – SEKISUI• IFCC-Robert Shaffer Award for Outstanding Achievements in the Development of Standards
for Use in Laboratory Medicine Co-sponsored by NIST and CLSI – NIST/CLSI• IFCC Young Investigator Award (from 2011) – IFCC
• IFCC Hytest Distinguished Award for contributions to Cardiovascular Diagnostics - HYTESTThe budget of the FCC Distinguished Clinical Chemist Award will be shared with the IFCC Young
Investigator Award (from 2011) – IFCC.
18.
Foundation
EB received update from GB about Foundation’s activities
Laboratory-based surveillance training for communicable disease – Malawi
The training rearranged for October 2016 did not take place because of insufficient numbers.
Correspondence from David Isaboke, Laboratory Training Coordinator, AMREF Health Africa dated
3 October 2016 confirmed that the training would not now be available until 2017. The Board
considered various options and agreed that the project could carry over into 2017 and projectfunding could be retained by MAMLS provided that a written statement is forthcoming that it will not
be used for any other purpose
Lab Surfing’ social networking for Young Scientists - global
The Board reviewed the newly created website at www.lab-surfing.com. The Board agreed that thesite is attractive and should appeal to Young Scientists. GB was asked to contact the project leadfor information on the steps being taken to promote the site and the likely formal launch date.
Adopt a Professional’ - a collaboration with (SIBioC) in Italy
The Board noted the significant progress with this project including: the memorandum of
understanding between FEN and SIBioC has been signed. SIBioC has commenced fundraising. To
date a total of €10,500 has been received in the FEN account and a further €3500 has been
pledged. This is sufficient to support the training of two individuals, starting in January 2017. The
Board noted that it is the responsibility of FEN to recruit candidates for training. Accordingly, GB has
written criteria for selecting candidates. These criteria have been approved by the FEN Board andhave been shared with SIBioC. It is hoped to commence recruitment shortly.
Fundraising: the FEN Board discussed a report from the Chair. It was noted that fundraising isproving more difficult than anticipated. Despite several inquiries no significant progress has been
made in persuading external sponsors to support FEN. A variety of factors have emerged fromthese inquiries: very low global interest rates mean that many charities have had to cut back on theirannual charitable donations, some charities indicate that they are unable to receive any new
applications as funds are fully committed. This is especially the case for the charities associatedwith diagnostics companies, although some of the major international foundations support global
health their programmes tend to be focussed on high profile areas like infectious disease and/or
children, it would certainly help if FEN had a list of projects awaiting funding so that we canapproach sponsors for support for specific projects (e.g. ‘Adopt a Professional’), some IFCC
Member societies have indicated a willingness to work with FEN but have not suggested suitableprojects.
In discussion the Board agreed that: the outcome was disappointing but not altogether surprising
given the current global financial uncertainty, it would be useful to identify a range of specific11projects. To do this would mean altering the funding model so that project applications need notnecessarily be considered for direct funding from FEN at the next Board meeting, fundraising efforts
should continue with a view to seeking consideration for 2017 funding support.
The IFCC Medal for Outstanding Service
The 1st call for nominations has been sent, deadline December 31st.
13.0 IFCC Statutes and Rules
no specific items
19.0

Meetings
Executive Board meetings in 2017:- Milan, February 23th 2017 SWOT analysis; February 24th-25th 2017 EB- Athens, before the EuroMedLab Congress: June 9th-10th, 2017
- Durban, before the WorldLab Congress: October 20th - 21st, 201712